Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease
Completed
VU University Medical Center
Phase 2
This is a phase 2b, double-blind, placebo controlled proof-of-concept study of a an oral
small molecule selective inhibitor of p38 alpha kinase, neflamapimod, administered for 24
weeks in subjects with mild Alzheimer's disease. The primary objective is to demonstrate
significant improvement relative to placebo-treatment in episodic memory function, as
assessed by the Hopkins Verbal Learning Test. Secondary endpoints include Clinical Dementia
Rating scale (CDR), Wechsler Memory Scale (WMS), Mini-Mental-Status-Examination (MMSE) and
Cerebrospinal fluid (CSF) biomarkers of AD disease activity and progression.
Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease
Completed
Worldwide Clinical Trials
Phase 2
This is a phase 2b, double-blind, placebo controlled proof-of-concept study of a an oral
small molecule selective inhibitor of p38 alpha kinase, neflamapimod, administered for 24
weeks in subjects with mild Alzheimer's disease. The primary objective is to demonstrate
significant improvement relative to placebo-treatment in episodic memory function, as
assessed by the Hopkins Verbal Learning Test. Secondary endpoints include Clinical Dementia
Rating scale (CDR), Wechsler Memory Scale (WMS), Mini-Mental-Status-Examination (MMSE) and
Cerebrospinal fluid (CSF) biomarkers of AD disease activity and progression.
Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease
Completed
EIP Pharma Inc
Phase 2
This is a phase 2b, double-blind, placebo controlled proof-of-concept study of a an oral
small molecule selective inhibitor of p38 alpha kinase, neflamapimod, administered for 24
weeks in subjects with mild Alzheimer's disease. The primary objective is to demonstrate
significant improvement relative to placebo-treatment in episodic memory function, as
assessed by the Hopkins Verbal Learning Test. Secondary endpoints include Clinical Dementia
Rating scale (CDR), Wechsler Memory Scale (WMS), Mini-Mental-Status-Examination (MMSE) and
Cerebrospinal fluid (CSF) biomarkers of AD disease activity and progression.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
